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OBJECTIVES: Olanzapine and risperidone are the two most
widely used second-generation antipsychotic medications by Cal-
ifornia Medicaid (Medi-Cal) patients with severe mental disor-
ders. This analysis investigates the factors associated medication
choice by Medi-Cal patients with bipolar disorders who restart
therapy after a break in treatment. METHOD: Paid claims data
were analyzed to identify antipsychotic ‘re-starter’ treatment
episodes initiated between January 1999 and March 2003. An
episode was deﬁned each time a patient re-started therapy on a
new medication or restarted the same drug after a break of 15
days or more. Only re-starter episodes with olanzapine or risperi-
done were selected if 6 months of pre-treatment and 12 months
of post-treatment data were available. Multivariate logistic
regression was used to investigate the factors that affected treat-
ment choice. RESULTS: A total of 90,282 treatment episodes
meet study selection criteria. Olanzapine was the initial medica-
tion in 56% of re-starter episodes. Mean age was 39 and the
mean duration of uninterrupted treatment was 170 days.
Patients in every age category over 25 years of age were between
24% to 46% more likely to receive olanzapine, as were Asian
patients (+11%) and patients with prior use of psychiatric hos-
pital care (+6%). The likelihood of using olanzapine also
increased signiﬁcantly with the cost of non-institutional care con-
sumed in the prior 6 months. Risperidone patients were more
likely to be female (+10%), AFDC recipients (21%), urban
(+6%) or rural (6%) residents, Hispanic (+7%), black (+9%),
other minority (+7%) diabetic (+23%) and have a history of
prior nursing home use (+10%)(p < 0.05 for all results). CON-
CLUSION: Physicians in California used olanzapine and risperi-
done differentially to treat bipolar disorders. The observed
differences in patient characteristics for olanzapine and risperi-
done patients will affect both treatment outcomes and post-
treatment costs and must be adjusted for before comparing 
the outcomes achieved using these agents.
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OBJECTIVES: In a direct comparison of patients with bipolar
manic or mixed episodes, olanzapine and risperidone showed
similar efﬁcacy in mania ratings (Baker, APA 2003), but olanza-
pine had greater efﬁcacy on clinician global impression of sever-
ity (CGI-S). We performed a post-hoc analysis investigating
possible determinants of this differential treatment effect.
METHODS: This 3-week, double-blind study compared olan-
zapine (5–20mg/day; N = 165) to risperidone (1–6mg/day; N =
164) in manic or mixed episodes. Path analysis dissected the
CGI-S treatment effect into drug effect explainable by effects on
manic, depressive and extrapyramidal symptoms, measured 
by standard rating scales, versus other treatment effects not
accounted for by rating scales. Demographic and disease char-
acteristics were examined to determine if they were signiﬁcant
predictors of CGI-S improvement. Analysis of variance and
regression models used change from baseline to endpoint (last
observation carried forward) for all analyses. RESULTS: Olan-
zapine-treated patients achieved signiﬁcantly greater improve-
ment in CGI-S than risperidone-treated patients (p = 0.014).
While changes in manic and depressive symptoms were signiﬁ-
cant predictors of the change in CGI-S (both p < 0.001), treat-
ment effect remained statistically signiﬁcant (p = 0.006) even
after adjustment for change in these effects. In fact, 93% of olan-
zapine’s superior treatment effect on CGI-S was not attributable
to changes in mania, depression, or extrapyramidal symptoms.
Race, gender, rapid cycling status, manic vs. mixed diagnosis, age
of disease onset, and weight change were not signiﬁcant deter-
minants of CGI-S change. A signiﬁcant interaction was detected
between age and treatment: older olanzapine-treated patients
had greater CGI improvement compared to older risperidone
patients; no differences occurred between treatments for younger
patients. CONCLUSIONS: Rating scale, demographic, and
illness characteristics were at most modest determinants of
improvement in global illness severity. Even after adjusting for
signiﬁcant determinants, olanzapine-treated patients still experi-
enced signiﬁcantly greater improvement than risperidone-treated
patients in global illness severity.
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OBJECTIVE: American Psychiatric Association (APA) practice
guidelines do not recommend antidepressant monotherapy in
patients with bipolar disorder, given the risk of precipitating a
switch into mania. However, few data have provided empirical
evidence to support such a guideline from the population per-
spective. This study assesses the clinical and economic impact 
of antidepressant monotherapy in patients with bipolar dis-
order. METHODS: Subjects with bipolar disorder were identi-
ﬁed among continuously enrolled adult members in a national
managed care plan between January 1997 and June 2002. A total
of 34,493 monotherapy episodes for 13,016 bipolar patients
were deﬁned based on the computerized diagnosis and pharmacy
records. Log-transformed multivariate models were employed to
identify the relationship between the type of monotherapy (mood
stabilizers, antidepressants, or antipsychotics) and 6-month
bipolar-related health care costs after the treatment discontinu-
ation. RESULTS: Antidepressant monotherapy use was highly
prevalent in this patient population, with rates ranging from
55% to 64% over the 5-year period. Controlling for age, gender,
regional differences, and disease severity, bipolar-related health
care costs signiﬁcantly increased with longer duration of antide-
pressant monotherapy (p < 0.0001). However no such relation-
ship was observed with mood stabilizer monotherapy (p = 0.36)
or antipsychotic monotherapy (p = 0.37). This increase in costs
with antidepressant monotherapy was due to an increased risk
of manic switching (1.3% per person-month) compared to mood
stabilizer use (p < 0.0001). CONCLUSIONS: This study pro-
vides evidence of adverse clinical and economic outcomes fol-
lowing antidepressant use in a bipolar population. In spite of the
known risk of manic switching with antidepressant monother-
apy, use remained high from 1997–2002. Systematic educational
efforts are needed to communicate treatment guidelines.
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OBJECTIVE: The California Medicaid program (Medi-Cal) 
initiated open access to atypical antipsychotic medications in
October 1997. This analysis evaluates the impact of open access
on drug therapy outcomes and treatment costs in patients with
bipolar disorder. METHODS: We conducted a retrospective
database analysis of patients diagnosed with bipolar disorder
